Cutaneous Lupus Erythematosus
Immunology·MeSH: Lupus Erythematosus, Cutaneous
Prevalence
75.0 / 100K
4 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| biib059 | BIOGEN INC. (BIIB) |
Phase 2(1)
| Drug | Company |
|---|---|
| sar443122 | Sanofi (SNY) |
Phase 1(1)
| Drug | Company |
|---|---|
| Litifilimab | BIOGEN INC. (BIIB) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| imvt-1402 | Roivant Sciences Ltd. (ROIV) |
Compare drugs
Frequently asked questions
How many drugs are in development for Cutaneous Lupus Erythematosus?
BioSniper tracks 4 drugs in development for Cutaneous Lupus Erythematosus across 3 companies.
How many clinical trials target Cutaneous Lupus Erythematosus?
There are 2 clinical trials targeting Cutaneous Lupus Erythematosus tracked by BioSniper.
What is the prevalence of Cutaneous Lupus Erythematosus?
The estimated prevalence of Cutaneous Lupus Erythematosus is approximately 75.0 per 100,000 population.
Deep-dive into Cutaneous Lupus Erythematosus
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis